Verastem files patent for combination treatment of FAK inhibitor and immunotherapy for cancer
Discover how Verastem Inc.'s patent combines FAK inhibitors with immunotherapeutic agents like anti-PD-1 to enhance cancer treatment efficacy in humans. Explore the innovative method targeting immune checkpoint blockade pathways.
Discover how Verastem Inc.'s patent combines FAK inhibitors with immunotherapeutic agents like anti-PD-1 to enhance cancer treatment efficacy in humans. Explore the innovative method targeting immune checkpoint blockade pathways.
What's Your Reaction?
